Recently, the "2025 PDI Pharmaceutical R&D & Innovation Conference and China Drug R&D Top 100 List Release Ceremony," jointly guided by China Pharmaceutical University, China Pharmaceutical Enterprise Management Association, and the National Pharmaceutical Technology Market Association, was held in Chongqing. Under the theme of "Laying the Foundation, Gathering Momentum, Transforming, and Embracing the New," the conference brought together numerous authoritative industry experts and pharmaceutical enterprise representatives to explore the future landscape of pharmaceutical innovation from cutting-edge perspectives.

During the event, the conference unveiled the "2025 China Pharmaceutical R&D Strength Ranking" alongside a series of specialized lists including the Traditional Chinese Medicine Ranking, Chemical Medicine Ranking, and Biopharmaceutical Ranking. Tianjin Pharma Da Ren Tang secured a spot in the TOP 20 of the "2025 China Traditional Chinese Medicine R&D Strength Ranking," while Tianjin Pharma made the TOP 100 of the "2025 China Chemical Medicine R&D Strength Ranking."

The China Pharmaceutical R&D Capability Ranking, pioneered and released by YaoZhi.com in 2016, has been published for ten consecutive years and has become one of the most authoritative and influential R&D capability evaluation systems in China's pharmaceutical and healthcare industry.

This year's rankings were calculated by the Expert Committee of the Pharmaceutical R&D Strength Rankings and the Organizing Committee of the 2025 PDI Pharmaceutical R&D & Innovation Conference based on relevant data including 2024 drug acceptance and approval status, pharmaceutical companies' R&D investment, clinical trials, patent information, and historical R&D rankings.

In recent years, Tianjin Pharmaceuticals Group has adhered to the strategy of market-driven and technology-enabled development. Centering on its positioning of "Focusing on Innovation, Precise Positioning, Continuous Deepening, and Integration of R&D, Production, and Sales," and following the requirements of "High Level, High Standards, and Internationalization," the Group has strengthened scientific research and innovation in pharmaceuticals, medical devices, wellness products, and functional cosmetics. It has established an innovation framework comprising 2 national-level enterprise technology centers, 2 academician workstations, 1 municipal-level technology innovation center, 8 municipal-level enterprise technology centers, and 6 Tianjin key laboratories, with over 200 ongoing R&D projects. The Group has received one National First Prize for Scientific and Technological Progress, three National Second Prizes, and 28 provincial/ministerial-level First and Second Prizes for Scientific and Technological Progress. It has undertaken over 100 national and provincial/ministerial-level science and technology projects.

The inclusion of both enterprises on this list highlights Tianjin Pharmaceuticals Group's robust R&D capabilities in traditional Chinese medicine and chemical pharmaceuticals. Moving forward, the Group will leverage its clustered research platforms to deepen industry-academia-research-application integration, continuously delivering high-quality products that meet patient needs. This commitment aims to safeguard public health and advance innovation and upgrading within the pharmaceutical sector, contributing greater strength from Tianjin's pharmaceutical industry.